In the BioHarmony Drug Report Database

"Preview" Icon

Enasidenib mesylate

Idhifa (enasidenib mesylate) is a small molecule pharmaceutical. Enasidenib mesylate was first approved as Idhifa on 2017-08-01. It is used to treat myeloid leukemia acute in the USA. Idhifa’s patents are valid until 2034-09-16 (FDA).

 

Trade Name

 

Idhifa
 

Common Name

 

enasidenib mesylate
 

ChEMBL ID

 

CHEMBL3989931
 

Indication

 

myeloid leukemia acute
 

Drug Class

 

Mutated isocitrate dehydrogenase (IDH) inhibitors

Image (chem structure or protein)

Enasidenib mesylate structure rendering